Systemic rituximab in multifocal primary cutaneous follicle centre lymphoma

Acta Dermato-Venereologica

Volumn 91, Issue 5, 2011, Pages 562-567

  Quéreux, Gaëlle ^a   Brocard, Anabelle ^a   Peuvrel, Lucie ^a   Nguyen, Jean Michel ^a   Knol, Anne Chantal ^a   Dréno, Brigitte ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Cutaneous lymphoma; Follicle centre lymphoma; Rituximab

Indexed keywords

GAMMA INTERFERON; RITUXIMAB;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIFOCAL PRIMARY CUTANEOUS FOLLICLE CENTRE LYMPHOMA; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; SKIN LYMPHOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052010280     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-1113     Document Type: Article

References (28)

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
2. Zinzani PL, Quaglino P, Pimpinelli N, Berti E, Baliva G Rupoli S, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 2006; 24: 1376-1382.
3. Senff NJ, Noordijk Em, Kim yH, Bagot m, Berti E, Cerroni L, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008; 112: 1600-1609.
4. Fink-Puches R, Zenahlik P, Back B, Smolle J, Kerl H, Cerroni L. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observsed in a large group of patients. Blood 2002; 99: 800-80
5. Smith BD, Glusac EJ, McNiff JM, Smith GL, Heald PW, Cooper DL, et al. Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol 2004; 22: 634-639.
6. Pandolfino TL, Siegel RS, Kuzel TM, Rosen ST, Guitart J. Primary cutaneous B-cell lymphoma: review and current concepts. J Clin Oncol 2000; 18: 2152-2168
7. Smith mR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359-7368.
8. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635-2642.
9. molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev med 2008; 59: 237-250.
10. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 2005; 52: 847-853
11. Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas an applicational observation. Br J Dermatol 2005; 153: 167-173.
12. morales AV, Advani R, Horwitz SM, Riaz N, Reddy S, Hoppe RT, et al. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol 2008; 59: 953-957.
13. Valencak J, Weihsengruber F, Rappersberger K, Trautinger F, Chott A, Streubel B, et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol 2009; 20: 326-330.
14. Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-484
15. Kennedy GA, Blum R, McCormack C, Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases. Australas J Dermatol 2004; 45: 34-37
16. Errante D, Bernardi D, Bianco A, De Nardi S, Salvagno L. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma. Ann Oncol 2006; 17: 1720-1721
17. Vidal L, Gafter-Gvili A, Leibovici L, Dreyling m, Ghielmini m, Hsu Schmitz SF, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009; 101: 248-255
18. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-4840
19. Rijlaarsdam JU, Toonstra J, meijer OW, Noordijk Em, Willemze R. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy. J Clin Oncol 1996; 14: 549-555
20. Eich HT, Eich D, micke O, Suttzer H, Casper C, Krieg T, et al. Long-term efficacy, curative potential, and prognostic factors of radiotherapy in primary cutaneous B-cell lymphoma. Int J Radiat Oncol Biol Phys 2003; 55: 899-906
21. Senff NJ, Hoefnagel JJ, Neelis KJ, Vermeer MH, Noordijk EM, Willemze R. Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol 2007; 143: 1520-1526
22. Piccinno R, Caccialanza M, Berti E. Dermatologic radiotherapy of primary cutaneous follicle center cell lymphoma. Eur J Dermatol 2003; 13: 49-52
23. Bekkenk MW, Vermeer MH, Geerts ML, Noordijk EM, Heule F, van Voorst Vader PC, et al. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. J Clin Oncol 1999; 17: 2471-2478
24. Paul T, Radny P, Krober SM, Paul A, Blaheta HJ, Garbe C. Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol 2001; 144: 1239-1243
25. Heinzerling L, Dummer R, Kempf W, Schmid mH, Burg G. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol 2000; 136: 374-378
26. Kerl K, Prins C, Saurat JH, French LE. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol 2006; 155: 1197-1200
27. Roguedas AM, Watier H, Paintaud G, De Muret A, Vaillant L, Machet L. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma. Br J Dermatol 2005; 152: 541-544
28. Gamo R, Calzado L, Pinedo F, Lopez-Estebaranz JL. Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab. Actas Dermosifiliogr 2008; 99: 291-296